本报道最初发表于Endpoints News。请点击这里查看原文
There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn this the hard way is Wave Life Sciences, which said Thursday that its obesity candidate yielded weight loss of just 1% more than placebo in an early-stage study.
许多公司纷纷研发基于胰高血糖素样肽-1（GLP-1）的抗肥胖药物是有原因的：其他方法往往无效。最新吃到苦头的生物科技公司是Wave Life Sciences，该公司周四表示，其减重候选药物在一项早期研究中减重效果仅比安慰剂多1%。
您已阅读10%（453字），剩余90%（3986字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。